Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
- Registration Number
- NCT05639647
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants.
The study is seeking participants who are:
* 9 months to less than 18 years of age
* Hospitalized
* Suspected/known to have a gram-negative infection
* Receiving intravenous (iv, given directly into a vein) antibiotics
* Being treated for complicated infections of various body parts that includes the abdomen, urinary tract, blood stream, and lungs.
* Participants will receive either ATM-AVI or best available therapy (BAT).
* Both therapies will be given through a vein.
* Participants with complicated abdominal infections will also receive iv Metronidazole (MTZ). Patients with cIAI and Cockayne Syndrome are excluded due to a risk of severe hepatotoxicity with the use of MTZ. - Participants on ATM-AVI treatment who have anaerobic infections will also receive iv MTZ at the study doctor's discretion.
* The iv dose of ATM-AVI will be based on the participant's weight and kidney function.
* The study doctor will determine the iv dose of BAT.
* During the first 2 study days, participants on ATM-AVI therapy will have 5 blood draws in small quantities.
* Starting on day 4, the study doctor will decide if participants may be switched to oral therapy.
* Participants will receive a maximum of 14 days of ATM-AVI treatment.
* After discharge from the hospital, 1 study visit may be required.
* Depending on the participant's response, the study duration will be from 33 to 50 days.
* The investigator will contact participants by phone 28 to 35 days after the last study treatment to check participants health status.
- Detailed Description
* Following informed consent, potential participants who are hospitalized, receiving IV antibiotics for less than 24 hours within 48 hours of randomization or failed antibiotic therapy for greater than 48 hours and have suspected/known gram-negative bacterial infections with a complex intra-abdominal infection (cIAI), complex urinary tract (cUTI), blood stream infection (BSI), hospital acquired pneumonia or ventilator associated pneumonia (HAP/VAP) will be screened.
* Although cultures are required, isolation of the causative pathogen is not a criteria for enrollment. - cUTI participants requiring systemic prophylactic antibiotics for any reason at screening are allowed to enter the study provided they discontinue this medication prior to first study drug dose.
* If the participant satisfies the inclusion and exclusion requirements, the participant will be randomly enrolled in a ratio of 3 iv ATM-AVI for each iv BAT.
* A total of 48 participants at approximately 33 sites will be randomized using interactive response technology (IRT).
* The study will be multicenter, international and open label with a single blinded observer assigned by each investigational site.
* There will be 4 cohorts with ages 12 to less than 18 years (Cohort 1), 6 to less than 12 years (Cohort 2), 2 to less than 6 years (Cohort 3) and 9 months to less than 2 years (Cohort 4).
* Each cohort will have 12 participants for a total of 48 participants.
* Cohorts 1 and 2 will be enrolled simultaneously. - - Cohort 3 will begin enrollment after the first 4 participants complete Cohort 2 and PK data and safety have been reviewed by the sponsor and an external data monitoring committee (DMC). Then ATM-AVI dose may be adjusted as needed.
* Cohort 4 will begin enrollment after the first 4 participants completed Cohort 3 and the PK data have been reviewed by the sponsor and the DMC. Then the ATM-AVI dose may be adjusted as needed.
* After 4 participants complete Cohort 4 the PK data will be review by the sponsor and DMC and then the ATM-AVI dose may be adjusted as needed.
* Enrollment will not be paused during the PK data reviews of the first 4 ATM-AVI participants in a cohort. If the ATM-AVI dose requires adjustment, the cohort 4 number will be increased to 20 with 15 receiving ATM-AVI and 5 BAT.
* All participants in the ATM-AVI group will receive an initial ATM-AVI loading dose and then maintenance doses every 6 or 8 hours depending on the participant's weight and kidney function.
* ATM-AVI will be infused over 3 hours.
* Those with cIAI will receive metronidazole (MTZ). Patients with cIAI and Cockayne Syndrome are excluded due to a risk of severe hepatotoxicity with the use of MTZ. - At the investigator's discretion MTZ will be administered to those with BSI, cUTI or HAP/VAP and an associated anaerobic infection.
* MTZ will be administered iv over 20 to 30 minutes starting.
* Optional gram-positive coverage with vancomycin, teicoplanin and linezolid is permitted. Daptomycin is only permitted for cIAI and BSI participants.
* Coverage with iv aminoglycoside is permitted for Pseudomonas aeruginosa.
* Concerning concomitant medications, participants with cUTI may not take prophylactic therapy during study drug treatment.
* Systemic antibiotics are not permitted unless the study drug failed, or it is for a remote site infection essential for participant's safety.
* Systemic iv antivirals are permitted.
* Systemic antifungals should be avoided unless indicated.
* Meropenem/carbapenem-type antibiotics cannot be given concomitantly with ATM-AVI.
* Probenecid and inhaled antibiotics are to be avoided from informed consent until the end of iv treatment (EOIV).
* Antibiotic peritoneal lavage is not permitted. Non-antibiotic lavage is permitted.
* The primary endpoints are pharmacokinetics (PK) and safety.
* Five PK micro-blood samples of at least 0.1 mL will be drawn. The initial 2 PK micro blood samples will be drawn at 2 hours and 5 hours after the first infusion. The next 3 PK micro-blood samples will be drawn at 15 minutes before, 5 hours and 5 3/4 hours after the 5th infusion or a later infusion.
* ATM and AVI clearance (CL), maximum (Cmax) and minimum (Cmin) venous blood concentration, area under the curve (AUC) and half-life (t1/2) will be analyzed.
* A blinded observer (BO), assigned by each investigational site, will clinically assess the participants every day.
* The BO will evaluate causality of all adverse events (AEs) and serious adverse events (SAEs) while the participant is in the hospital, within 24 hours of the end of iv study drug (EOIV), and within 48 hours of end of treatment for those switched to oral therapy.
* For the secondary endpoint of efficacy, the BO will clinically assess the test of cure (TOC) within 7 to 14 days of the last antibiotic treatment. Potential for liver function abnormalities and acute kidney injury will be specifically monitored in addition to standard of care assessments.
* Cure is defined as signs and symptoms improved with no further antimicrobial treatment required except for adjunctive gram-positive therapy or for Pseudomonas aeruginosa.
* In addition, for cIAI participants, no unplanned drainage or surgical intervention is necessary since the initial surgical procedure. Only for those switched to oral therapy before 14 days, improvement is afebrile with absence of new signs or symptoms and improvement of 1 or more symptoms or signs with no worsening of signs or symptoms.
* Failure is defined as death, requirement of antibiotics for the index infection, or discontinuation due to an AE(s). cIAI participants have additional failure criteria of requiring surgical intervention and/or have an infected post-surgical wound(s).
* Participant may choose to permanently discontinue and are free to discontinue treatment without further treatment prejudice. Possible reasons for permanent discontinuation are:
* Condition under investigation resolved prior to minimum treatment period
* AE or any other condition posing a risk to a participant or jeopardizing safety
* Investigator, national coordinators, medical monitor, and/or Sponsor decided it is in the best interest of the participant's safety
* Positive pregnancy test during the treatment period
* Absence of explanation for liver injury and/or increase in liver function tests or acute kidney toxicity
* Discontinuation of intervention does not represent withdrawal from the study and participants should remain in the study until the end of the study (EOS).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 48
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ATM-AVI ATM-AVI ATM-AVI administered iv every 6 or 8 hours and dosed according to participant's weight and kidney function for up to 14 days depending on response. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv ATM-AVI therapy Best available therapy (BAT) BAT BAT will be selected by the investigator and administered iv. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv BAT
- Primary Outcome Measures
Name Time Method Maximum Predicted Plasma Concentration (Cmax) of ATM and AVI Up to 15 Days Cmax is the maximum plasma concentration of ATM and AVI as population pharmacokinetic (popPK) analysis predicts.
Plasma Decay Half-Life (t1/2) Up to 15 Days Half-life is the time measured for the plasma concentration of ATM and AVI to decrease by one half as popPK analysis predicts.
Apparent Clearance (CL) Up to 15 Days ATM and AVI clearance is a quantitative measure of the rate at which ATM and AVI are removed from the blood (rate at which ATM and AVI are metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.
Proportion of Participants reporting Adverse Events (AE) Baseline up to Day 50 Proportion of participant AE reports of vital signs, physical examinations, and clinical laboratory tests overall and by age cohort. For each AE the last assessment made prior to the first dose of study drug will be defined as the baseline.
Minimum Predicted Trough Plasma Concentration (Cmin) of ATM and AVI Up to 15 Days Cmin is the minimum trough plasma concentration of ATM and AVI as popPK analysis predicts.
Area under the Concentration-Time Curve (AUC) of ATM-AVI Up to 15 Days AUC is a measure of the plasma concentration of ATM and AVI overtime as popPK analysis predicts.
Proportion of Participants reporting Serious Adverse Events (SAE) Baseline up to Day 50 Proportion of participant SAE reports of vital signs, physical examinations, and clinical laboratory tests overall and by age cohort. For each SAE the last assessment made prior to the first dose of study drug will be defined as the baseline.
Proportion of Participants reporting AEs resulting in death Baseline up to Day 50 Proportion of Participants reporting AE resulting in death from baseline. For each death the last assessment made prior to the first dose of study drug will be defined as the baseline
Proportion of Participants reporting liver injury and acute kidney injury of ATM-AVI relative to Best Available Therapy (BAT) Baseline up to Day 50 Proportion of Participants reporting liver injury and acute kidney injury of ATM-AVI relative to Best Available Therapy (BAT) from baseline. For each report of liver and acute kidney injury the last assessment made prior to the first dose of study drug will be defined as the baseline
Proportion of Participants reporting AEs leading to discontinuation Baseline up to Day 50 Proportion of Participants reporting AEs leading to discontinuation from baseline. For each discontinuation the last assessment made prior to the first dose of study drug will be defined as the baseline
- Secondary Outcome Measures
Name Time Method Perentage of participants with favorable clinical response (CR) at end of iv study treatment (EOIV) Up to 15 days after iv study drug treatment EOIV favorable CR is baseline signs and symptoms have improved such that with in 24hours after iv study treatment stopped, or premature discontinuation of the study drug or early withdrawal from the study no further antimicrobial treatment for the index infection is required. In addition, for cIAI participants, no unplanned drainage or surgical intervention is necessary since the initial procedure.
Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) EOT within 48 hours after last dose of oral switch therapy or at time of premature discontinuation of study drug or early withdrawal from study EOT is only for those that were switched to oral therapy a favorable CR is baseline signs and symptoms have improved such that after study treatment, no further antimicrobial treatment for the index infection is required. In addition for cIAI participants, no unplanned drainage or surgical intervention is necessary since the initial procedure.
Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Up to 15 Days after last study treatment A TOC favorable CR is baseline signs and symptoms have improved such that after up to 14 days of study treatment, no further antimicrobial treatment for the index infection is required. In addition for cIAI participants, no unplanned drainage or surgical intervention is necessary since the initial procedure.
Percentage of participants with Favorable Microbiological Response at end of iv study drug treatment (EOIV) EOIV within 24 hours after last iv study drug infusion Eradication (or urine quantification \<103 CFU/mL for cUTI participants) of causative pathogen from an appropriately obtained specimen at the site of infection and presumed eradication specific to cIAI and HAP/VAP participants when repeat culture of specimens were not performed or clinically indicated in a participant who had a clinical response of cure
Percentage of Participants with Favorable Microbiological Response at End of Treatment (EOT) EOT within 48 hours after last dose of oral switch therapy or at time of premature discontinuation of study drug or early withdrawal from study Eradication (or urine quantification \<103 CFU/mL for cUTI participants) of causative pathogen from an appropriately obtained specimen at the site of infection and presumed eradication specific to cIAI and HAP/VAP participants when repeat culture of specimens were not performed or clinically indicated in a participant who had a clinical response of cure in participants who were switched to oral therapy
Percentage of Participants with Favorable Microbiological Response at test of cure (TOC) Up to 15 Days Eradication (or urine quantification \<103 CFU/mL for cUTI participants) of causative pathogen from an appropriately obtained specimen at the site of infection and presumed eradication specific to cIAI and HAP/VAP participants when repeat culture of specimens were not performed or clinically indicated in a participant who had a clinical response of cure.
Trial Locations
- Locations (36)
Sahaydri Super Speciality Hospital, Nagar road
🇮🇳Pune, Maharashtra, India
Hospital Universitario HM Monteprincipe
🇪🇸Boadilla del Monte, Madrid, Spain
Rady Children's Hospital
🇺🇸San Diego, California, United States
Weill Cornell Medicine-New York Presbyterian Hospital
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Mount Sinai Kravis Children´s Hospital
🇺🇸New York, New York, United States
The Mount Sinai Hospital
🇺🇸New York, New York, United States
Le Bonheur Children's Hospital
🇺🇸Memphis, Tennessee, United States
Beijing Children's Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
The Children's Hospital of Chongqing Medical University
🇨🇳Chongqing, Chongqing, China
Guangzhou Women and Children's Medical Center
🇨🇳Guangzhou, Guangdong, China
Shanghai Children's Medical Center
🇨🇳Shanghai, China
Chengdu Women and Children Center Hospital
🇨🇳Chengdu, Sichuan, China
Oblastni nemocnice Kolin
🇨🇿Kolin 3, Kolín, Czechia
Krajska Zdravotni, Nemocnice Most
🇨🇿Most, Czechia
University General Hospital of Heraklion
🇬🇷Heraklion, Irakleío, Greece
Ippokrateio General Hospital of Thessaloniki
🇬🇷Thessaloniki, Kentrikí Makedonía, Greece
Bajai Szent Rókus Kórház
🇭🇺Baja, Bács-kiskun, Hungary
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Nirmal Hospital Pvt Ltd.
🇮🇳Surat, Gujarat, India
RajaRajeswari Medical College and Hospital
🇮🇳Bengaluru, Karnataka, India
Institute of Child Health
🇮🇳Kolkata, WEST Bengal, India
Hospital Germans Trias i Pujol
🇪🇸Badalona, Barcelona [barcelona], Spain
Hospital Sant Joan de Déu
🇪🇸Esplugues de Llobregat, Barcelona [barcelona], Spain
Hospital Universitario La Paz
🇪🇸Madrid, Madrid, Comunidad DE, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hsinchu Municipal Mackay Children's Hospital
🇨🇳Hsinchu City, Hsinchu, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch
🇨🇳Taoyuan, Taiwan
Cukurova Universty
🇹🇷Sarçam, Adana, Turkey
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi
🇹🇷Istanbul, İ̇stanbul, Turkey
S.B.Ü. Dr. Behçet Uz Çocuk Hastaliklari Ve Cerrahisi Eğitim Ve Araştirma Hastanesi
🇹🇷İzmir, İ̇zmir, Turkey
Çukurova Üniversitesi Tıp Fakültesi Adana Hastanesi
🇹🇷Adana, Turkey